Tela Bio, Inc. Stock Price, News & Analysis

TELA Bio, Inc. has announced its participation in the JMP Securities Life Sciences Conference on June 16, 2022, at 11:00 am ET. The company, which focuses on innovative soft-tissue reconstruction solutions, aims to optimize clinical outcomes by preserving and restoring the patient's own anatomy. Interested parties can access a live and archived webcast of the presentation through TELA's investor relations page. TELA Bio is dedicated to providing advanced, cost-effective solutions that minimize long-term exposure to synthetic materials, enhancing natural healing.

TELA Bio, Inc. (NASDAQ: TELA) announced a new credit facility with MidCap Financial, granting access to $50 million in total credit. This includes $40 million received at closing and an additional $10 million available under specific conditions. The new facility allows TELA to repay a previous $30 million debt, enhancing financial flexibility with minimal further capital needed. The facility matures on May 1, 2027, and carries an interest rate of 6.25% plus SOFR. TELA aims to bolster its business objectives and growth initiatives using these funds.

MALVERN, Pa., May 26, 2022 – TELA Bio, Inc. (TELA), a commercial-stage medical technology company, announced its participation in the Jefferies Healthcare Conference on June 8, 2022. The management of TELA is set to present at 4:30 PM ET, and the live webcast can be accessed at their official site. TELA is dedicated to innovative soft-tissue reconstruction solutions that enhance clinical outcomes while preserving the patient's anatomy. The company aims to provide surgeons with economically effective technologies that utilize the natural healing process.

TELA Bio reported a 40% revenue growth in Q1 2022, totaling $8.2 million, driven by increased demand for OviTex products. OviTex PRS sales surged by 111%. The company maintains a gross profit of $5.0 million, with a gross margin of 61%. However, operating expenses rose to $14.8 million, leading to a net loss of $10.9 million. Despite challenges from COVID-19, TELA projects full-year revenue between $40 million to $45 million, a 36% to 53% increase over 2021.

MALVERN, Pa., May 09, 2022 – TELA Bio, Inc. (NASDAQ: TELA), a medical technology company, will participate in the 2022 H.C. Wainwright Annual Global Investment Conference on May 24, 2022. The company focuses on innovative soft-tissue reconstruction solutions that enhance clinical outcomes by preserving patients' anatomy. Management will present virtually at 7 am ET, with a live and archived webcast available on their investor relations website.

TELA Bio, Inc. (NASDAQ: TELA) announced the approval of stock options for 13 newly-hired employees, totaling 50,950 shares. The options, with an exercise price of $9.00 per share, were granted on April 27, 2022, under Nasdaq Rule 5635(c)(4) as part of their employment compensation. The options will vest over four years, with 25% vesting after one year and the remainder in monthly installments. The company's focus is on innovative soft-tissue reconstruction solutions that optimize clinical outcomes by preserving the patient's anatomy.

TELA Bio, Inc. (NASDAQ: TELA) announced it will report its first quarter 2022 financial results on May 10, 2022, at 4:30 p.m. ET. The call will provide insights into the company’s performance in soft-tissue reconstruction solutions that prioritize patient anatomy restoration. Interested parties can access the conference by dialing specific numbers for U.S./Canada and international participants, or via the company's investor website. TELA emphasizes its commitment to innovative, economically effective healthcare solutions while cautioning that forward-looking statements carry inherent risks.

TELA Bio, Inc. announced the hiring of D. Taylor Ocasio as the new General Counsel. With nearly ten years in corporate law and healthcare, Ocasio previously served as Deputy General Counsel at Zynerba Pharmaceuticals and held positions at Catalent Pharma Solutions and prominent law firms. CEO Antony Koblish expressed confidence in Ocasio's extensive knowledge in life sciences and corporate securities, highlighting his potential contributions to TELA's growth. TELA focuses on innovative soft-tissue reconstruction solutions that enhance clinical outcomes by preserving the patient's anatomy.

TELA Bio, a medical technology company, announced its participation in the Needham & Co. 21st Annual Healthcare Virtual Conference on April 12, 2022, at 2:15 PM ET. TELA Bio focuses on soft-tissue reconstruction solutions that prioritize preserving the patient's anatomy. Management will present at the conference, and interested parties can access the live and archived webcast via their investor relations website. TELA Bio is committed to providing advanced technologies that enhance clinical outcomes while reducing reliance on permanent synthetic materials.